BiotechTube

Brimonidine + Brimonidine Mono Therapy + sodium carboxymethylcellulose + Corticosteroid Eye Drop

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye

Conditions

Dry Eye

Trial Timeline

Sep 6, 2017 → Mar 29, 2018

NCT ID
NCT03418727

About Brimonidine + Brimonidine Mono Therapy + sodium carboxymethylcellulose + Corticosteroid Eye Drop

Brimonidine + Brimonidine Mono Therapy + sodium carboxymethylcellulose + Corticosteroid Eye Drop is a phase 2 stage product being developed by Ocugen for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT03418727. Target conditions include Dry Eye.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03418727Phase 2Completed

Competing Products

20 competing products in Dry Eye

See all competitors
ProductCompanyStageHype Score
Cyclosporine Ophthalmic 0.05% Ophthalmic EmulsionSight SciencesPre-clinical
15
OK-101 + PlaceboOKYO PharmaPhase 2
44
ISV 101Sun PharmaceuticalPhase 2
52
CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
85
0.09% cyclosporine A ophthalmic solutionSun PharmaceuticalPre-clinical
23
Cyclosporine + Artificial tearSun PharmaceuticalApproved
85
nanomicellular cyclosporine 0.09% + LifitegrastSun PharmaceuticalApproved
85
Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
85
Investigational Lubricating Eye Drop in a Novelia® bottle + Blink® Tears eye DropsJohnson & JohnsonPhase 2
52
diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.Santen PharmaceuticalPre-clinical
23
Diquafosol sodium 3% + Sodium hyaluronate 0.1%Santen PharmaceuticalPhase 2
52
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionSanten PharmaceuticalPhase 3
77
Placebo ophthalmic solution and 3% DE-089 ophthalmic solutionSanten PharmaceuticalPhase 1
33
DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
SHR8028 eye drops + Vehicle eye drops.Jiangsu Hengrui MedicinePhase 3
77
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
77
ABBV-444 + REFRESH OPTIVE UDAbbViePhase 3
77
AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic SolutionAbbViePhase 1/2
41
ABBV-444AbbViePhase 3
77
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)AbbViePre-clinical
23

Other Products from Ocugen

Brimonidine Tartrate + PlacebosPhase 3
72
Brimonidine Tartrate + PlacebosPhase 3
72
OCU410STPhase 2/3
60
BBV152Phase 2/3
60
OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye DosingPhase 1/2
36